Laboratory Evaluation of Hypercoagulability

Initial Basic Coagulation Screening

• Perform a complete blood count with platelet count, prothrombin time/INR, activated partial thromboplastin time, and a basic chemistry panel first to detect acquired coagulopathies and establish a baseline before specialized thrombophilia testing. 1

• D‑dimer can be used for risk stratification in patients with a prior thrombotic event, but its low specificity limits diagnostic utility. 1

Genetic Thrombophilia Testing

• Factor V Leiden (R506Q) mutation is the most common inherited thrombophilia, accounting for > 90 % of hereditary activated protein C resistance; high‑quality evidence supports routine testing for this mutation. Evidence level: high. 2

• When patients are receiving direct oral anticoagulants, activated protein C resistance assays should be avoided unless the assay has been validated as insensitive to DOACs. Evidence level: moderate. [2][3]

Lupus Anticoagulant (LA) Testing

• Two parallel assays are required for LA detection: dilute Russell’s viper venom time (dRVVT) and a lupus‑anticoagulant‑sensitive aPTT. Evidence level: strong. 4

• Positive LA screening results must be followed by mixing studies and confirmatory testing for each assay. Evidence level: strong. 4

• If testing must be performed while the patient is on warfarin with an INR of 1.5–3.0, a 1:1 dilution of the patient’s plasma with normal pooled plasma is recommended, although interpretation remains challenging. Evidence level: moderate. 5

• Using both dRVVT and LA‑sensitive aPTT together detects LA in the vast majority of cases; omitting either test can lead to under‑diagnosis in up to 55 % of triple‑positive patients. Evidence level: strong. 4

Anticardiolipin and Anti‑β2‑Glycoprotein I Antibody Testing

• Measure anticardiolipin (aCL) and anti‑β2‑glycoprotein I (aβ2GPI) antibodies by ELISA for IgG, IgM, and IgA isotypes. Evidence level: strong. 4

• Moderate‑to‑high titer thresholds are defined as ≥ 40 Units (moderate) and ≥ 80 Units (high). Evidence level: strong. 4

• The combination of medium‑high titers of aCL and aβ2GPI of the same isotype (most often IgG) together with a positive LA identifies patients at the highest risk for thrombosis. Evidence level: strong. 5

Timing and Pre‑analytical Considerations

• Avoid laboratory testing during an acute thrombotic event or while the patient is on anticoagulation therapy, because acute‑phase reactants (e.g., Factor VIII) may be elevated and full‑dose heparin or warfarin prolong baseline clotting times. Evidence level: strong. [1][5]

• Warfarin: obtain testing 1–2 weeks after discontinuation or when INR < 1.5. Evidence level: moderate. 5

• Heparin (LMWH): ensure the last dose is administered > 12 hours before blood draw. Evidence level: moderate. 5

• Repeat antiphospholipid antibody assays on two or more occasions at least 12 weeks apart to confirm persistent positivity and satisfy diagnostic criteria for antiphospholipid syndrome. Evidence level: strong. 4

Interpretation Pitfalls to Avoid

• Do not interpret protein C, protein S, or antithrombin results during acute thrombosis or while the patient is receiving anticoagulation, as levels are altered by consumption and treatment effects. Evidence level: moderate. 5

• Do not rely solely on aPTT for LA screening; it fails to detect LA in 50–60 % of affected patients. (This limitation is documented in the literature but not directly cited in the provided references.)

• Do not stop evaluation after a single positive LA result; always assess aCL and aβ2GPI antibodies because triple‑positive patients carry the greatest thrombotic risk. Evidence level: strong. [4][5]

Clinical Indications for Comprehensive Testing

• Patients presenting with idiopathic venous thromboembolism before age 50, recurrent thrombosis, or thrombosis at unusual sites (e.g., cerebral venous or mesenteric vein) should undergo the full hypercoagulability work‑up. Evidence level: moderate. 1

Thrombophilia Testing Recommendations

Initial Laboratory Evaluation

• For a 55-year-old male with a strong family history of blood clots, testing should include Factor V Leiden, Prothrombin 20210A, and functional coagulation assays for antithrombin III, protein C, and protein S, along with plasma homocysteine measurement, as recommended by the American College of Medical Genetics 6, 7
• Complete blood count (CBC), prothrombin time (PT), and activated partial thromboplastin time (aPTT) should be ordered as basic screening tests, according to the American Society of Hematology 8
• Factor V Leiden (R506Q) mutation testing is indicated as the primary genetic test for inherited thrombophilia, with a high level of evidence supporting its use 6, 7
• Prothrombin 20210A variant testing should be performed simultaneously with Factor V Leiden testing, as it is the second most common inherited thrombophilia, with moderate evidence supporting its use 6, 7
• Plasma homocysteine level measurement is recommended rather than MTHFR genetic testing, as hyperhomocysteinemia interacts synergistically with Factor V Leiden, with moderate evidence supporting its use 7
• Functional coagulation assays for antithrombin III, protein C, and protein S deficiencies should be included in the panel, with high evidence supporting their use 6, 7

Rationale for Testing Selection

• Factor V Leiden and Prothrombin 20210A mutations are the most common inherited thrombophilias and are easily detected through DNA testing, with high evidence supporting their use 7
• Venous thrombosis is multifactorial, and the presence of more than one genetic risk factor is not uncommon, justifying panel testing, with moderate evidence supporting its use 6, 7
• A strong family history of venous thrombosis increases the likelihood of identifying heritable thrombophilic defects, though the correlation is not perfect, with low evidence supporting its use 6
• Protein S, protein C, and antithrombin III deficiencies are too genetically heterogeneous for routine molecular genetic testing but can be assessed through functional assays, with moderate evidence supporting their use 7

Additional Testing to Consider

• D-dimer testing may be useful for risk stratification in patients with previous thrombotic events, with moderate evidence supporting its use, as recommended by the International Society on Thrombosis and Haemostasis 9
• Residual vein occlusion detected by venous ultrasound does not predict recurrence risk to a clinically useful degree, with low evidence supporting its use, as stated by the International Society on Thrombosis and Haemostasis 9

Common Pitfalls to Avoid

• Testing for the Factor V R2 allele (H1299R) is not currently indicated in routine thrombophilia workup, with high evidence supporting its avoidance, as recommended by the American College of Medical Genetics 6
• Testing for MTHFR gene variants is less informative than direct measurement of plasma homocysteine levels, with moderate evidence supporting its avoidance, as stated by the American College of Medical Genetics 7